Unlearn, a startup developing an AI-powered “digital twin” service of patients for clinical trials, raises a $50M Series B led by Insight Partners
Context & Ripple Effects
Unlearn's digital-twin pitch has been compounding since its $12M Series A in 2020: build AI profiles of trial participants so control arms can be partly simulated rather than fully enrolled. This $50M Series B, led by Insight Partners, is the middle beat of that arc — the round that carries the service from research tooling toward commercial deployment with trial sponsors.
The investor choice matters as much as the amount: Insight Partners has a pattern of leading $50M-scale Series B rounds in vertical AI, including Clinc's $52M healthcare-and-banking round in 2019. The later coverage confirms the thesis held — Unlearn went on to add OpenAI CTO Mira Murati to its board at a $265M valuation and then close a $50M Series C pushing total funding past $130M.
First-order effects
- Unlearn gains the capital to scale its digital-twin service to more trial sponsors, with Insight Partners now holding a lead position in a clinical-AI company it can shepherd alongside its other healthcare portfolio bets.
- Sponsors running trials with Unlearn can shrink control-arm enrollment, directly cutting per-trial patient recruitment costs — the core selling point the round funds.
Second-order effects
- Rival clinical-AI vendors face pressure to match the twin-based design: Health Data Analytics Institute's predictive-outcomes API and RapidAI's imaging-analysis funding show the same 'AI substitutes for clinical data collection' race forming across adjacent categories.
- Insight's repeat pattern of leading ~$50M Series B rounds in healthcare AI raises the competitive bar for other funds chasing the sector's mid-stage deals.
Third-order effects
- If digital twins keep winning sponsor and eventually regulatory acceptance, clinical trials structurally shift toward smaller human cohorts with simulated control arms — changing how evidence is generated and how regulators validate AI-derived comparators.
The trend: Clinical research is moving toward AI-generated digital twins that substitute for enrolled control patients, with venture capital funding the transition round by round.